Egcg, a dyrk1a Inhibitor as Therapeutic Tool for Reversing Cognitive Deficits in Down Syndrome Individuals.
Status:
Completed
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
There is a mounting evidence of the modulation properties of the major catechin in green tea,
epigallocatechin-3-gallate (EGCG), on dual specificity tyrosine-phosphorylation-regulated
kinase 1A (DYRK1A) gene overexpression in the brains of DS mouse models.The aims are to
investigate the clinical benefits and safety of EGCG administration in young adults with DS,
to establish short-term EGCG effects (three months) on neurocognitive performance, and to
determine the persistency or reversibility of EGCG related effects after three months of
discontinued use.